 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 3971 | 回復(fù): 16 | ||||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | ||||
wachina至尊木蟲 (知名作家)
|
[交流]
武田fasiglifam (TAK-875)宣告失敗，恒瑞呋格列泛齒亡唇寒 已有16人參與
|
|||
|
Takeda terminates development activities for fasiglifam (TAK-875) Takeda Pharmaceutical Company Limited (Takeda) announced that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. Patient safety is Takeda's highest priority. The company has worked with three independent panels of experts to provide for the safety of trial participants and ensure independent safety oversight for the clinical trials throughout the duration of the fasiglifam (TAK-875) Phase 3 development program. The expert panels include the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program, reviews the unblinded clinical data from program trials and provides continual safety oversight of trial subjects and recommendations. The DMC is comprised of clinical experts in endocrinology, cardiology and hepatology as well as a statistician. The independent Liver Safety Evaluation Committee (LSEC) is comprised of five hepatologists with expertise in drug-induced liver injury. While remaining blinded to treatment information, the LSEC regularly evaluates data on liver enzymes elevations and adjudicates cases that impacted the liver. In addition, an independent Executive Committee (EC) provides additional oversight for the fasiglifam (TAK-875) cardiovascular outcomes trial. After careful consideration of the data emerging from all the clinical trials and in consultation with these panels, the company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks. For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam. 作為慢性疾病：糖尿病的治療，肝毒性太致命了，難怪武田揮淚斬馬謖。值得一提的是，恒瑞也向CFDA申報了GPR-40激動劑呋格列泛，現(xiàn)在心里估計(jì)也是拔涼拔涼的 |
回復(fù)此樓» 收錄本帖的淘帖專輯推薦
 新藥仿藥 |
» 猜你喜歡
腦梗怎么治療
已經(jīng)有3人回復(fù)
-
腦梗怎么治療
已經(jīng)有0人回復(fù)
-
藥物學(xué)論文潤色/翻譯怎么收費(fèi)?
已經(jīng)有196人回復(fù)
-
如何高效的測量腺病毒的粒徑和電位
已經(jīng)有0人回復(fù)
-
生物組織中有目標(biāo)分析物，專屬性怎么做
已經(jīng)有0人回復(fù)
-
26在職申博—生物與醫(yī)藥—抗體/ADC藥物方向，江浙滬，有項(xiàng)目，可帶資。
已經(jīng)有1人回復(fù)
-
288分求調(diào)劑
已經(jīng)有0人回復(fù)
-
一志愿蘇州大學(xué) 生物技術(shù)與工程（086001） 初試323分，求調(diào)劑
已經(jīng)有0人回復(fù)
-
三年實(shí)驗(yàn)室工作經(jīng)歷，一志愿華中農(nóng)業(yè)大學(xué)微生物，總分288求調(diào)劑
已經(jīng)有0人回復(fù)
091602
鐵桿木蟲 (小有名氣)
- 應(yīng)助: 65 (初中生)
- 金幣: 11932.2
- 散金: 9
- 紅花: 4
- 帖子: 203
- 在線: 2295.2小時
- 蟲號: 826350
- 注冊: 2009-08-12
- 性別: GG
- 專業(yè): 藥物合成
7樓2013-12-31 08:51:06
2樓2013-12-30 12:41:43
guri
鐵蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 74
- 帖子: 6
- 在線: 9.6小時
- 蟲號: 2285814
- 注冊: 2013-02-18
- 性別: GG
- 專業(yè): 藥物設(shè)計(jì)與藥物信息
3樓2013-12-30 13:06:43
wph75623
銅蟲 (小有名氣)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 159.9
- 帖子: 137
- 在線: 54.9小時
- 蟲號: 1922830
- 注冊: 2012-08-03
- 專業(yè): 合成藥物化學(xué)
4樓2013-12-30 16:49:55
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 301求調(diào)劑 +10 | yy要上岸呀 2026-03-17 | 10/500 |
|
|---|---|---|---|---|
|
|
[考研] 265求調(diào)劑 +9 | 梁梁校校 2026-03-17 | 9/450 |
|
|
[考研] 328求調(diào)劑，英語六級551，有科研經(jīng)歷 +4 | 生物工程調(diào)劑 2026-03-17 | 8/400 |
|
|
|
[考研] 304求調(diào)劑 +6 | 曼殊2266 2026-03-18 | 6/300 |
|
|
|
[考研] 南京大學(xué)化學(xué)376求調(diào)劑 +3 | hisfailed 2026-03-19 | 6/300 |
|
|
|
[考研] 330求調(diào)劑 +4 | 小材化本科 2026-03-18 | 4/200 |
|
|
|
[考研]
 材料與化工 322求調(diào)劑
+4
|
然11 2026-03-19 | 4/200 |
|
|
|
[考研] 353求調(diào)劑 +3 | 拉鉤不許變 2026-03-20 | 3/150 |
|
|
|
[考研] 0703化學(xué)調(diào)劑 ，六級已過，有科研經(jīng)歷 +13 | 曦熙兮 2026-03-15 | 13/650 |
|
|
|
[考研] 材料學(xué)碩318求調(diào)劑 +5 | February_Feb 2026-03-19 | 5/250 |
|
|
|
[考研] 生物學(xué)調(diào)劑招人�。�！ +3 | 山海天嵐 2026-03-17 | 4/200 |
|
|
|
[考研] 一志愿西安交通大學(xué)材料工程專業(yè) 282分求調(diào)劑 +5 | 楓橋ZL 2026-03-18 | 7/350 |
|
|
|
[考研] 一志愿福大288有機(jī)化學(xué)，求調(diào)劑 +3 | 小木蟲200408204 2026-03-18 | 3/150 |
|
|
|
[考研] 收復(fù)試調(diào)劑生 +4 | 雨后秋荷 2026-03-18 | 4/200 |
|
|
|
[考博] 26申博 +4 | 八6八68 2026-03-16 | 4/200 |
|
|
|
[考研] 一志愿，福州大學(xué)材料專碩339分求調(diào)劑 +3 | 木子momo青爭 2026-03-15 | 3/150 |
|
|
|
[考研] [導(dǎo)師推薦]西南科技大學(xué)國防/材料導(dǎo)師推薦 +3 | 尖角小荷 2026-03-16 | 6/300 |
|
|
|
[考研] 一志愿211 0703方向310分求調(diào)劑 +3 | 努力奮斗112 2026-03-15 | 3/150 |
|
|
|
[考研] 070300化學(xué)學(xué)碩求調(diào)劑 +6 | 太想進(jìn)步了0608 2026-03-16 | 6/300 |
|
|
|
[考研] 求老師收留調(diào)劑 +4 | jiang姜66 2026-03-14 | 5/250 |
|